Fanconi's Anemia Clinical Trial
Verified date | July 2004 |
Source | Office of Rare Diseases (ORD) |
Contact | n/a |
Is FDA regulated | No |
Health authority | Unspecified |
Study type | Interventional |
OBJECTIVES: I. Determine the probability of engraftment with total body irradiation,
cyclophosphamide, fludarabine, and anti-thymocyte globulin followed by HLA nongenotypically
identical donor, T-cell depleted hematopoietic cell transplantation in patients with
Fanconi's anemia.
II. Determine the incidence of acute and chronic graft-versus-host disease in these patients
after undergoing this treatment regimen.
III. Determine the one-year survival rate in these patients after undergoing this treatment
regimen.
IV. Determine the toxicity of this treatment regimen in these patients. V. Determine the
incidence of relapse in patients with myelodysplastic syndrome or acute myeloid leukemia
after undergoing this treatment regimen.
Status | Completed |
Enrollment | 30 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A to 34 Years |
Eligibility |
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Patients with a diagnosis of Fanconi's anemia AND Aplastic anemia OR Myelodysplastic syndrome OR Acute leukemia with or without chromosomal anomalies Aplastic anemia as defined by having at least one of the following: Platelet count less than 20,000/mm3 Absolute neutrophil count less than 500/mm3 Hemoglobin less than 8 g/dL - Myelodysplastic syndrome with multilineage dysplasia With or without chromosomal anomalies - Hematologic malignancy (e.g., acute myeloid leukemia, acute lymphoblastic leukemia, or B-cell non-Hodgkin's lymphoma) - No greater than 30% blasts in bone marrow or greater than 5% blasts in peripheral blood - No active CNS leukemia at time of transplantation - Must have an HLA A, B, DRB1 identical or 1 antigen mismatched related (nonsibling) or unrelated bone marrow, peripheral blood, or umbilical cord blood donor --Prior/Concurrent Therapy-- - Radiotherapy: No prior radiotherapy that would preclude total body irradiation - Surgery: Not specified --Patient Characteristics-- - Performance status: Karnofsky 70-100% OR Lansky 50-100% - Hematopoietic: See Disease Characteristics - Hepatic: No hepatic failure (e.g., coagulopathy or ascites) - Renal: Creatinine clearance at least 40 mL/min - Cardiovascular: Ejection fraction at least 45% - Other: No active uncontrolled infection within one week of transplantation No malignant solid tumor (e.g., squamous cell carcinoma of the head, neck, or cervix) within 2 years of transplantation Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception |
Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Minnesota Cancer Center | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
University of Minnesota - Clinical and Translational Science Institute |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03609827 -
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
Active, not recruiting |
NCT00005896 -
Phase I Pilot Study of CD34 Enriched, Fanconi's Anemia Complementation Group C Gene Transduced Autologous Peripheral Blood Stem Cell Transplantation in Patients With Fanconi's Anemia
|
Phase 1 | |
Completed |
NCT00005891 -
Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Fanconi's Anemia
|
N/A | |
Completed |
NCT00005892 -
Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia
|
N/A | |
Completed |
NCT00001749 -
Medical Treatment for Diamond Blackfan Anemia
|
Phase 2 | |
Completed |
NCT03609814 -
Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)
|
||
Completed |
NCT00004378 -
Stem Cell Transplantation (SCT) for Genetic Diseases
|
N/A | |
Completed |
NCT00001399 -
Gene Therapy for the Treatment of Fanconi's Anemia Type C
|
Phase 1 | |
Completed |
NCT00004787 -
Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure Syndromes
|
Phase 2 | |
Active, not recruiting |
NCT00006127 -
Phase I Study of Amifostine in Patients With Bone Marrow Failure Related to Fanconi's Anemia
|
Phase 1 |